Gilead Submits NDA for a Novel Treatment of Indolent Non-Hodgkin's Lymphoma

Gilead is announcing that they have submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration for approval of idelalisib, an investigational, targeted, oral inhibitor of PI3K delta for the treatment of indolent non-Hodgkin's lymphoma.

Specifically, idelalisib is designed for patients with indolent non-Hodgkin's lymphomas that are refractory to rituximab and to alkylating agent-containing chemotherapy (common sense suggests this would refer to commonly prescribed drugs for indolent NHLs such as doxorubicin, such as can be found in the CHOP regimen).

Said John C. Martin, PhD, Chairman and Chief Executive Officer of Gilead Sciences:

Gilead is committed to advancing a pipeline of novel cancer therapies that have the potential to improve the lives of patients. Based on the rate and duration of response observed to date in this highly refractory iNHL patient population, we believe idelalisib could become an important new therapy for patients who have limited treatment options.

A new class of therapies

The NDA for idelalisib is supported by data from a single-arm, open-label Phase 2 study (Study 101-09) of 125 patients with indolent NHLs refractory to rituximab and to alkylating-agent-containing chemotherapy. Interim data analysis presented in June at the International Conference on Malignant Lymphoma in Lugano, Switzerland, demonstrated that single-agent idelalisib achieved an overall response rate of 53.6 percent, with a median duration response of 11.9 months.

Idelalisib is an investigational, targeted, highly selective oral inhibitor of phosphoinositide 3-kinase (PI3K) delta, a protein critical for the activation, proliferation and survival of B lymphocytes. PI3K delta signaling is hyperactive in many B-cell lymphomas and leukemias, and drives proliferation, survival and trafficking to lymphoid tissue. Idelalisib is being developed as a single agent and in combination with approved and investigational therapies.

If ultimately approved, Idelalisib would become the first PI3K delta targeted therapy approved for a blood cancer and the first in a new class of therapies approved for indolent NHLs in more than 10 years.

Source: MarketWatch

More Articles

More Articles

This entry looks at Non Hodgkin's Lymphoma in the lungs, clinically known as pulmonary lymphoma, one of the subtypes of lymphoma. 'Lymphoma' is an...

In order to prevent developing any subtype of lymphoma, it would be helpful to know the causes of lymphoma. Unfortunately, in virtually every case...

BEAM chemotherapy is an acronym representing a small family of combination chemotherapy regimens that are used chiefly as salvage regimens in the...

There are two types of cancer: benign and malignant. Benign cancers are the kind that don't spread and don't threaten one's life. Malignant...

The Erythrocyte Sedimentation Rate (ESR - sometimes called sed rate or sedimentation rate) is a nonspecific screening test for various...

Blood counts can be used to identify disease and monitor patient health during cancer treatments. Though these tests cannot diagnose lymphoma on...

MALT lymphoma is a rare B-cell non-Hodgkin's lymphoma that typically runs an indolent or slow-growing clinical...

Mantle cell lymphoma (MCL) is just one of 50-60 known B-cell subtypes of...

After some of the dust has settled, the thoughts of many new lymphoma patients turn to diet and nutrition. They want to know if, in the past,...

According to a study by Japanese researchers, the SMILE combination chemotherapy protocol is effective against extranodal natural killer/T-cell...

In a perfect world, every case of cancer would respond to, and be cured by first-line therapy. Unfortunately, it is not often the case. This is...

Patients treated with maintenance rituximab had three times longer progression-free survival. This is a summary of an article published in the...

Prednisone is a glucocorticosteroid (a steroid) used in the treatment of many types of cancers. It functions as an anti-inflammatory medicine that...

In 1964, researchers at the National Cancer Institute developed the first combination chemotherapy that cured a...

Since so many chemotherapy agents can affect a patient’s sex drive and fertility, thinking about these issues prior...